Elisa J de Koning1,2, Paul Lips1,3, Brenda W J H Penninx1,4, Petra J M Elders1,5, Annemieke C Heijboer6, Martin den Heijer3, Pierre M Bet7, Harm W J van Marwijk5,8, Natasja M van Schoor1,2. 1. Amsterdam Public Health Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands. 2. Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands. 3. Department of Internal Medicine, Endocrine Section, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands. 4. Department of Psychiatry, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands. 5. Department of General Practice and Elderly Care Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands. 6. Department of Clinical Chemistry, Endocrine Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands. 7. Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands. 8. Division of Primary Care and Public Health, Brighton and Sussex Medical School, University of Brighton, Falmer, Brighton, United Kingdom.
Abstract
BACKGROUND:Depressive symptoms and impaired physical functioning are prevalent among older adults. Supplementation with vitamin D might improve both conditions, particularly in persons with low vitamin D status. OBJECTIVE: The D-Vitaal study primarily aimed to investigate the effect of vitamin D supplementation on depressive symptoms, functional limitations, and physical performance in a high-risk older population with low vitamin D status. Secondary aims included examining the effect of vitamin D supplementation on anxiety symptoms, cognitive functioning, mobility, handgrip strength, and health-related quality of life. METHODS: This study was a randomized placebo-controlled trial with 155 participants aged 60-80 y who had clinically relevant depressive symptoms, ≥1 functional limitations, and serum 25-hydroxyvitamin D [25(OH)D] concentrations of 15-50/70 nmol/L (depending on season). Participants received 1200 IU/d vitamin D3 (n = 77) or placebo tablets (n = 78) for 12 mo. Serum 25(OH)D was measured at baseline and 6 mo; outcomes were assessed at baseline, 6 mo, and 12 mo. Linear mixed-models analyses were conducted to assess the effect of the intervention. RESULTS: The supplementation increased serum 25(OH)D concentrations in the intervention group to a mean ± SD of 85 ± 16 nmol/L compared with 43 ± 18 nmol/L in the placebo group after 6 mo (P < 0.001). No relevant differences between the treatment groups were observed regarding depressive symptoms, functional limitations, physical performance, or any of the secondary outcomes. CONCLUSIONS:Supplementation with 1200 IU/d vitamin D for 12 mo had no effect on depressive symptoms and physical functioning in older persons with relatively low vitamin D status, clinically relevant depressive symptoms, and poor physical functioning. This trial is registered with the Netherlands Trial Register (www.trialregister.nl) under NTR3845.
RCT Entities:
BACKGROUND:Depressive symptoms and impaired physical functioning are prevalent among older adults. Supplementation with vitamin D might improve both conditions, particularly in persons with low vitamin D status. OBJECTIVE: The D-Vitaal study primarily aimed to investigate the effect of vitamin D supplementation on depressive symptoms, functional limitations, and physical performance in a high-risk older population with low vitamin D status. Secondary aims included examining the effect of vitamin D supplementation on anxiety symptoms, cognitive functioning, mobility, handgrip strength, and health-related quality of life. METHODS: This study was a randomized placebo-controlled trial with 155 participants aged 60-80 y who had clinically relevant depressive symptoms, ≥1 functional limitations, and serum 25-hydroxyvitamin D [25(OH)D] concentrations of 15-50/70 nmol/L (depending on season). Participants received 1200 IU/d vitamin D3 (n = 77) or placebo tablets (n = 78) for 12 mo. Serum 25(OH)D was measured at baseline and 6 mo; outcomes were assessed at baseline, 6 mo, and 12 mo. Linear mixed-models analyses were conducted to assess the effect of the intervention. RESULTS: The supplementation increased serum 25(OH)D concentrations in the intervention group to a mean ± SD of 85 ± 16 nmol/L compared with 43 ± 18 nmol/L in the placebo group after 6 mo (P < 0.001). No relevant differences between the treatment groups were observed regarding depressive symptoms, functional limitations, physical performance, or any of the secondary outcomes. CONCLUSIONS: Supplementation with 1200 IU/d vitamin D for 12 mo had no effect on depressive symptoms and physical functioning in older persons with relatively low vitamin D status, clinically relevant depressive symptoms, and poor physical functioning. This trial is registered with the Netherlands Trial Register (www.trialregister.nl) under NTR3845.
Authors: A W Braam; M J Prince; A T F Beekman; P Delespaul; M E Dewey; S W Geerlings; S-L Kivela; B A Lawlor; H Magnusson; I Meller; K Pérès; F M Reischies; M Roelands; R A Schoevers; P Saz; I Skoog; C Turrina; A Versporten; J R M Copelan Journal: Br J Psychiatry Date: 2005-07 Impact factor: 9.319
Authors: Olivia I Okereke; Charles F Reynolds; David Mischoulon; Grace Chang; Nancy R Cook; Trisha Copeland; Georgina Friedenberg; Julie E Buring; JoAnn E Manson Journal: Contemp Clin Trials Date: 2018-03-08 Impact factor: 2.226
Authors: Chinnappa A Uthaiah; Narasimha M Beeraka; R Rajalakshmi; C M Ramya; SubbaRao V Madhunapantula Journal: Mol Neurobiol Date: 2022-04-27 Impact factor: 5.590
Authors: Olivia I Okereke; Charles F Reynolds; David Mischoulon; Grace Chang; Chirag M Vyas; Nancy R Cook; Alison Weinberg; Vadim Bubes; Trisha Copeland; Georgina Friedenberg; I-Min Lee; Julie E Buring; JoAnn E Manson Journal: JAMA Date: 2020-08-04 Impact factor: 56.272
Authors: Julia E Inglis; Isabel D Fernandez; Edwin van Wijngaarden; Eva Culakova; Jennifer E Reschke; Amber S Kleckner; Po-Ju Lin; Karen M Mustian; Luke J Peppone Journal: Nutr Cancer Date: 2020-09-11 Impact factor: 2.900